Skip to main content
Completed Clinical Trials

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

By April 24, 2017No Comments

Condition

Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung Cancer

Estimated Enrollment: 6

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science

Study ID Numbers: MORAb-009-006

Study First Received: January 7, 2011

Last Updated: September 28, 2016

Estimated Primary Completion Date: March 2013

 

Primary Outcome Measures:

Primary Objective: determine biodistribution of radiolabeled amatuximab in tumor and nontumor tissue|Secondary objectives: determine the safety of a single IV of Indium-CHX-A amatuximab|Pharmacokinetic and serum levels|uptake of Indium-CHX-A amatuximab|occurrence of HACA|correlate shed serum mesothelin to imaging

Sponsors and Collaborators:

Morphotek

Website Link: https://ClinicalTrials.gov/show/NCT01521325

Leave a Reply